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Abstract The DHA12 family of transporters contains a number of prokaryotic and eukaryote membrane proteins.
Some of these proteins share conserved sites intrinsic to substrate recognition, structural stabilization
and conformational changes. For this study, we chose the MdfA transporter as a model DHA12 protein
to study some general characteristics of the vesicular neurotransmitter transporters (VNTs), which all
belong to the DHA12 family. Two crystal structures were produced for E. coli MdfA, one in complex with
acetylcholine and the other with potential reserpine, which are substrate and inhibitor of VNTs,
respectively. These structures show that the binding sites of these two molecules are different. The Ach-
binding MfdA is mainly dependent on D34, while reserpine-binding site is more hydrophobic. Based on
sequence alignment and homology modelling, we were able to provide mechanistic insights into the
association between the inhibition and the conformational changes of these transporters.
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INTRODUCTION
MdfA, as a typical antiporter of the major facilitator
superfamily (MFS), has been the subject of extensive
study, especially in the research of multidrug transport
mechanisms (EdgarandBibi1997).Manysmallmolecules
are substrates ofMdfA, including neutral compounds such
as chloramphenicol (Cm) and thiamphenicol, lipophilic
cations such as tetraphenylphosphonium (TPP?) and
ethidium bromide (EtBr), and the zwitterionic drug—
ciproﬂoxacin (Adler and Bibi 2004). Crystal structures of
E. coliMdfA (ecMdfA) have recently been reported by our
laboratory (Heng et al. 2015). Based on the parsed
structures of ecMdfA, the key location for the binding of a
variety of substrates was determined to be the large
central cavity within MdfA, which is lined with mostly
hydrophobic residues. An acidic residue, D34, is also
present deep within this cavity, and is proposed to be
critical for the binding of certain substrates (Heng et al.
2015). Also, the substrate-boundcrystal structure ofMdfA
provided abase for further structural and functional study
of other homologous proteins, such asMdtM, anotherMFS
transporter, which share high sequence identity with
MdfA (Paul et al 2014).
In mammalian cells, vesicular monoamine trans-
porter (VMAT) and vesicular acetylcholine transporter
(VAChT) are homologous proteins with MdfA and
transport mono-positively charged amine neurotrans-
mitters and hormones from the cytoplasm and con-
centrate them within secretory vesicles by alternating
their access mechanism (Parsons 2000). They are sub-
classiﬁed into the SLC18 group of MFS in eukaryotes
(Lawal and Krantz 2013) and also belong to the DHA12
family (Paulsen et al. 1996; Putman et al. 2000; Heng
et al. 2015). Two isoforms of VMAT, 1 and 2, have been
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cloned and identiﬁed (Erickson et al. 1992). VMATs and
VAChT are predicted to possess 12 transmembrane
helices (TM) consisting of two pseudo-symmetrical
domains, and use the proton motive force (PMF) of the
transmembrane electrochemical proton gradient as the
driving force for the uptake of cytoplasmic substrates
into the vesicles (Zhang et al. 2015). Extensive phar-
macological studies have shown that VMATs and VAChT
have broad substrate speciﬁcity, and a large number of
substrates and inhibitors of VMATs and VAChT have
been identiﬁed (Yelin and Schuldiner 1995; Erickson
et al. 1996; Bravo et al. 2005). Several residues in these
proteins have been identiﬁed to contribute to substrate
recognition (Merickel et al. 1995; Finn and Edwards
1997), protonation and energy coupling (Yaffe et al.
2013).
To study the transport mechanisms of VMATs and
VAChT, a homology model based on LacY was initially
used to investigate the alternating access mechanism of
VMAT2 (Vardy et al. 2004; Yaffe et al. 2013). However,
owing to their low sequence similarity and the fact that
LacY is a symporter rather than antiporter, LacY is not
suitable for studying the proton/substrate antiport
mechanism of VMATs and VAChT. Unlike previous
passable symporter LacY, it is reasonable to assume that
the proton/substrate antiporter MdfA would be a better
reference for homology model and functional study of
VMATs and VAChT. Although MdfA and its eucaryotic
homologs share low sequence identity (Fig. S1), those
conserved motifs sharing in DHA12 family reﬂect the
fact that they possess similar proton-substrate
antiporting mechanism as discussed at length in previ-
ous paper(Heng et al. 2015). More importantly, several
well-known substrates of MdfA are also transported by
VAChT, including tetraphenylphosphonium, ethidium
and rhodamine (Bravo et al. 2005). An inhibitor of
VMATs, reserpine (Erickson et al. 1996), is also reported
to inhibit the translocation cycle of MdfA (Edgar and
Bibi 1999).
Reserpine is an antipsychotic and antihypertensive
drug used for the relief of psychotic symptoms, and
irreversibly blocks VMATs in the presynaptic neurons
(Preskorn 2007). Reserpine was proposed to directly
bind and competitively inhibit the efﬂux pump during
proton/substrate antiport (Holler et al. 2012).
To elucidate the transportation mechanism of VMATs
and VAChT and the potential inhibition mechanism of
reserpine towards multiple transporters, we therefore
used the ecMdfA structure as a model to investigate the
binding of acetylcholine (ACh) and reserpine molecules.
Here, we report the crystal structures of ecMdfA com-
plexed with ACh at 2.8-Å resolution using the soaking
method, and with possible reserpine at 3.5-Å resolution
using co-crystallization. Both of these structures
were captured in the inward-facing conformation,
albeit under different crystallization conditions. The
reserpine-MdfA complex structure shows more exten-
sive interactions between the transporter and substrate
than that observed within the ACh-MdfA complex. Based
on these ecMdfA structures, we could simulate the
docking of reserpine into a model of VAChT (Fig. 1). We
used this docked model to postulate a mechanism for
substrate transport and inhibitor binding for VAChT.
RESULTS
Acetylcholine (ACh)-bound structure of ecMdfA
The complexed structures of ecMdfA with ACh and
reserpine were obtained under two distinct crystalliza-
tion conditions. Their space groups were C2 and P3121,
respectively, and the structures were resolved with the
molecular replacement method (Table S1). In the two
crystal structures, the ﬁnal reﬁned structural models
contained the intact peptide chains of residues 10–400
and 14–400, respectively, and were both in the inward-
facing conformation consistent with the previously




Fig. 1 Possible inhibition mechanism for VAChT. Three conserved,
negatively charged residues of human VAChT (D46, E309 and
D398) line the pocket of the predicted VAChT structure. ACh and
reserpine are, respectively, represented with magenta and cyan
sticks. The N-terminal domain is shown in blue, and the C-terminal
domain is shown in yellow
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ACh-complex structure was obtained with the soaking
method, during which the pH value was increased from
5.4 to 8.0, using the same conditions under which
crystals of Dxc-ecMdfA were obtained and supple-
mented with 5 mmol/L ACh. We postulated that Dxc
could be replaced by ACh when the pH of crystallized
condition increases since key amino acids around the
binding cavity determine ecMdfA prefers to bind posi-
tively charged Ach rather than negatively charged Dxc.
Results of the structural studies showed no differences
between these two complexed structures, except for the
electron density of Dxc being replaced with that of ACh
(Fig. 2).
As expected, the resolved ACh-complex structure
shows that ACh indeed binds in the vicinity of the D34
residue. The distance between the positively charged
head group of ACh and the negatively charged side chain
of D34 is *4.5 Å, while residues Y30, L263, F358 and
M358 form hydrophobic interactions with ACh (Fig. 2).
We overlaid the potential protonation sites of the
VMATs or VAChT on the structure of ecMdfA based on
sequence alignment (Fig. S1). We found that three acidic
residues of VAChT, D33, E309 and D398, correspond
with residues E26, I239 and N331 of ecMdfA, respec-
tively, which are located near the ACh-binding pocket.
E309 is located at the bottom of the substrate-binding
cavity, and may play the same critical protonation-
deprotonation role as D34 in ecMdfA. Residue D33,
which corresponds with E26 on ecMdfA, has been
shown to take part in the recognition of positively
charged substrates (Merickel et al. 1995).
Reserpine-bound structure of ecMdfA
The second crystal structure we generated was of
reserpine-complexed ecMdfA. Reserpine is an effective
inhibitor of MdfA (Edgar and Bibi 1999). There were
two ecMdfA molecules in one asymmetric unit of the
P3121 structure. The interfaces are consisted of the
twelfth helices of ecMdfA, and comprised mostly
hydrophobic amino acids, such as L382, V386 and I389.
Both of the two transporters in the unit adopted an
inward-facing conformation (Fig. S2).
In this structure, we identiﬁed a suspected density
attributable to the presence of reserpine in the central
cavity. We built a reserpine molecule into the model at
this position to analyse its possible inhibition mecha-
nism. Reserpine occupies a more hydrophobic position
than ACh because it is a larger molecule. The
trimethoxybenzoyl in the tail of reserpine is near resi-
due D34. Hydrophobic interactions were localized on
the trimethoxybenzoyl group and other groups of the
reserpine molecule (Fig. 3). For comparison, in the











Fig. 2 ACh-binding sites of MdfA. ACh (magenta sticks) binds in
the pocket between the N- and C-terminal domains, which are
illustrated in white and yellow, respectively. The omit Fo-Fc density
(in red) for ACh is contoured at 3r. Three equivalent conserved
acid residues which may be important in substrate binding and













Fig. 3 Reserpine-binding site of MdfA. The backbone of MdfA is
shown in cartoon representation. Two important cavity helices,
TM1 and TM7, are coloured in cyan, while the other helices are in
white. The reserpine molecule is illustrated with yellow sticks.
Amino acid residues near reserpine are shown with green sticks.
The omit 2Fo-Fc density for reserpine is contoured in marine (1r)
and pink (0.4r). Hydrogen bonds between reserpine and N331 are
shown as dotted lines
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previous 2.0-Å resolution Dxc-complex structure of
ecMdfA, residue D34 was observed to form hydrogen
bond with Dxc, which exerts an inhibitory effect on the
Cm resistance of ecMdfA (Fig. 4). In contrast, three
methoxyls of reserpine were in proximity to the D34
residue, potentially forming hydrogen bonds for struc-
ture stabilization. In addition, both Dxc and reserpine
directly interact with residue P154 in the conserved
motif C of MdfA. The mechanism of reserpine inhibition
is therefore likely to be associated with motif C.
DISCUSSION
According to the multiple sequence alignment of the 12
transmembrane proton-dependent bacterial multidrug
transporters of the MFS family (also known as DHA12),
these transporters contain a number of highly con-
served motifs, which indicates that they may share a
similar transportation mechanism (Putman et al. 2000).
Here, we show the sequence alignments of VMATs and
VAChT from Homo sapiens, Mus musculus and Rattus
norvegicus (Fig. S1), including their conserved motifs.
Motif A is in the cytoplasmic loop between TM 2 and 3
of the MFS, with the most conserved residue being G73,
which has previously been clearly demonstrated in the
structure of YajR (Jiang et al. 2013). Motif C, motif D and
motif G (or motif C0) all contain a conserved proline
residue in their consensus sequences of TMs 5, 1 and
11, respectively. Proline, which is incapable of acting as
a hydrogen bond donor, often plays a role of helix
‘‘breaker’’ in the transmembrane helices of a-helical
membrane proteins (Chandrasekaran et al. 2006).
Based on the structures of the ecMdfA-ACh and
ecMdfA-reserpine complexes, we modelled a homology
structure of VAChT overlaid with ACh and reserpine
(Fig. 1). The homology VAChT model was cytoplasm-
facing and consisted of 12 transmembrane helices,
similar to the structure of ecMdfA. In addition, there
were three carboxyl residues, D46, E309 and D398,
located in TM1, 7 and 8, respectively, all within the
central cavity. In the ACh-VAChT complexed model, ACh
binds to E309 through negative–positive charge inter-
action. Residue E309 is located at the bottom of the
large hydrophobic substrate-binding pocket, corre-
sponding with the positioning of residue D34 of ecMdfA.
This conﬁrmed that D34 of MdfA is likely deprotonated
during the process of substrate binding as previously
proposed (Heng et al. 2015), as upon ligand binding,
E309 is likely to become similarly deprotonated. This
buried acidic residue is necessary for the recognition of
monovalent, positively charged substrates. In the
VAChT-reserpine-complexed model, it appeared that
residues D398 and E309 may form a hydrogen bond
network with reserpine. This observation may explain
the inhibition mechanism of reserpine, because this
hydrogen bond network would stabilize VAChT in the
cytoplasm-facing conformation, whereby inactivating it
(Darchen et al. 1989). Furthermore, Khare et al. (2010)
showed that both D398 and E309 directly bind with the
allosteric inhibitor—vesamicol, but only the E309 resi-
due can bind ACh, while D398 does not. These obser-
vations are consistent with our model.
Most members of the DHA12 family recognize mul-
tiple substrates and trigger conformational change upon
substrate binding. Why the binding of a variety of sub-
strates can drive the transportation cycle, while inhi-
bitor binding may stabilize them in only one of their two
possible conformations. The conserved proline in
VMATs and VAChTs offers a clue as to the mechanism of
substrate binding and the subsequent conformational
change exerted. Highly conserved prolines are located in
motif C, which is also known as the ‘‘antiporter motif’’
(De Jesus et al. 2005). Several conformationally sensi-
tive residues, including some prolines, have been iden-
tiﬁed in motif C in VMAT2 (Ugolev et al. 2013) and
VAChT (Luo and Parsons 2010). Here, we presented
structural information of motif C from ecMdfA (Fig. 5A,
B). Several prolines from TM1, 5 and 7 were observed to
cluster together to form a ‘‘bottleneck’’ in the 3D struc-
ture. Similar features of other DHA12 members have
been shown to inhibit solute leak inside the cell (De
Jesus et al. 2005). We named this structural motif ‘‘3D-
motif C’’, which consists of four helices each from the



















Fig. 4 Inhibition of MdfA chloramphenicol resistance by Dxc.
E. coli C43 (DE3) cells harbouring wild-type MdfA or vector only
were grown in the presence of increasing concentrations of
chloramphenicol supplemented with Dxc (1 mmol/L). Relative
growth was calculated from the cell density and measured by
culture absorption at 600 nm. Assays were done in quadruplicate,
plotting the average with error bars of ±1 SD
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N-terminal and C-terminal domains. We also found
another inward-facing MFS antiporter GlpT, an organic
phosphate/inorganic phosphate antiporter, which con-
tained a similar prolines cluster in the same location of
antiporter motif when GlpT was superposed on the
ecMdfA structure (Huang et al. 2003) (Fig. 5C). Molec-
ular dynamics simulations of GlpT are consistent with
the proposed mechanism that proline-induced ﬂexibility
in the TM helices is critical to the conformational change
of MFS pseudo-rigid body motions (D’Rozario and San-
som 2008). Based on this, a sketch map of the 3D-motif
C in mVAChT (mouse VAChT) could be postulated on the
basis of multiple sequence alignment and homology
modelling (Fig. 5D). Residue P333 of mVAChT differs
from 3D-motif C in MdfA and may facilitate the bending
of TM 8 towards the proline cluster, similarly to the role
of P263 in MdfA. Mutations near 3D-motif C of VMATs
have been shown to inﬂuence the transport rate by
affecting the rate-limiting step of the transport cycle
(Ugolev et al. 2013). Evidence of interactions between
P154 and inhibitors in the ecMdfA-Dxc and ecMdfA-
reserpine complexes points to the close association of
3D-motif C with inhibition. In short, the conserved
sequence of 3D-motif C may participate in the gating-
like movements of these transporters.
In conclusion, the structures reported here of ecMdfA
in complex with ACh and potential reserpine improve
our understanding of the mechanisms of multiple sub-
strate recognition of MdfA. Using sequence alignment of
the VMATs, VAChT and ecMdfA, several conserved resi-
dues and motifs were identiﬁed. Therefore, we were




























Fig. 5 Structural features of the 3D-motif C of MdfA and a schematic of the transportation model. A 3D-motif C of MdfA (PDB ID: 4ZP0)
viewed from the periplasmic side. Prolines are shown as blue sticks and Dxc is in yellow. B 3D-motif C of MdfA viewed parallel to the
membrane. C Superposition of the 3D-motif C of MdfA and GlpT. D Schematic of the 3D-motif C of mVAChT
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the ecMdfA structure, and the model had credibility
based on previously published biochemical results. The
3D-motif C was determined to likely play a critical role
in substrate transport and conformational change. Study
of ecMdfA-complexed structures and predicted models
may facilitate further research on the structure and
function of vesicular neurotransmitter transporters.
Certainly, the authentic structures of VNTs are neces-
sary to explain the mechanisms of substrates recogni-
tion and transport.
MATERIALS AND METHODS
Protein expression and puriﬁcation
The full-length MdfA gene was subcloned into the pET-
28a vector (Novagen) with a C-terminal His6-tag(Heng
et al. 2015). For protein expression, E. coli C43(DE3)
strain transformed with the recombinant plasmid was
cultured in Terriﬁc Broth supplemented with 25 lg/mL
kanamycin at 37 C and induced at an OD600nm of 0.8
with 0.5 mmol/L isopropyl-D-thiogalactoside (IPTG) at
16 C for 18 h. The cells were harvested by centrifu-
gation at 4000 g for 30 min, resuspended in buffer A
(20 mmol/L HEPES pH 7.2, 300 mmol/L NaCl, 10%
(v/v) glycerol and 5 mmol/L b-mercaptoethanol) and
then disrupted at 10,000–15,000 psi using a JN-R2C
homogenizer (JNBio, China). Cell debris was removed by
centrifugation at 17,000 g for 15 min. The supernatant
was ultracentrifuged at 100,000 g for 1 h. Membrane
fraction was harvested and solubilized with 0.5%
(w/v) n-decyl-b-D-maltopyranoside (DM; Anatrace) for
15 min at 4 C. We eluted the target proteins from 2 mL
Ni2?-nitrilotriacetate afﬁnity resin (Ni–NTA; Qiagen)
using 15 mL buffer A containing 300 mmol/L imidazole
and 0.2% (w/v) DM, and concentrated to about
10–15 mg/mL. The concentrated sample was incubated
with 0.8 mmol/L Cm and subsequently loaded onto a
Superdex-200 10/30 column (GE Healthcare) pre-
equilibrated with buffer B (20 mmol/L HEPES pH 7.2,
100 mmol/L NaCl and 5 mmol/L b-mercaptoethanol),
supplemented with mixed detergents of 0.2% (w/v) n-
nonyl-b-D-glucopyranoside (NG; Anatrace) and 0.025%
(w/v) n-dodecyl-N,N-dimethylamine-N-oxide (LDAO;
Anatrace). Cm (0.8 mmol/L) was added to the collected
protein, which was then concentrated to 20 mg/mL and
mixed with 0.5 mmol/L reserpine for crystallization.
Crystallization
Crystal screening was performed using the hanging
drop vapour-diffusion method (1 lL plus 1 lL over
200 lL) at 16 C and obtained under the conditions of
0.1 mol/L Tris (pH 8.0), 0.22 mol/L sodium citrate and
35% (v/v) PEG400 from the MemGold screening kit
(molecular dimensions). The crystals grew in
*2 months and were ﬂash-cooled in liquid nitrogen for
storage and data collection.
Data collection and structure determination
X-ray diffraction datasets were collected at Shanghai
Synchrotron Radiation Facility (SSRF) and processed
with the HKL-2000 software package (Otwinowski and
Minor 1997). The space group of the reserpine structure
was P3121, while the space group of ACh was C2. All
ligand-complex structures were resolved by molecular
replacement. There were two MdfA molecules per
crystallographic asymmetric unit for P3121. The model
was further reﬁned using the program Coot (Emsley and
Cowtan 2004). Model validation was carried out using
the web-based program MolProbity (Davis et al. 2004).
Inhibition of drug resistance assays
The E. coli C43 (DE3) strain was transformed with the
MdfA gene-containing pET28a plasmid. A single clone
was picked from LB-agar plates for inoculation into
5 mL LB supplemented with kanamycin (30 lg/mL)
and grown at 37 C. The cultures were induced with
0.5 mmol/L IPTG once an OD600nm of 0.6 was obtained,
and the cultures were incubated overnight for protein
expression. The cells were then diluted into 48-well
plates containing 1 mL LB with increasing concentra-
tions of the test drug (Cm) and kanamycin (30 lg/mL).
At the beginning of each typical experiment, the cell
density in the wells was 0.05 OD600nm units. Plates were
incubated at 37 C with shaking, and the cell density
was measured with a Varioskan Flash reader (Thermo
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